CELLCEUTIX PROVIDES UPDATE TO SHAREHOLDERS
My Fellow Cellceutix Shareholders,
We are pleased to inform you that this past Thursday (February 5th) we submitted an application to the NASDAQ Exchange for listing on the NASDAQ Capital Markets. We have already met ...
Read More »
KevetrinOur technology - Kevetrin™ targets both MDM2-p53 and Rb-E2F pathways in tumor suppression.
Read more »
PrurisolOur technology KM-133 acts through immune modulation and PRINS reduction
BrilacidinOur technology - Brilacidin is the first of a completely new class of antibiotics called defensin-mimetics
More News »
Sign Up to Receive Alerts on Cellceutix click here.
More information available at clinicaltrials.gov